|
**Overview**: Chromosome Karyotype Panel**Introduction**: The Chromosome Karyotype Panel is a diagnostic tool designed to detect chromosomal abnormalities using whole blood samples. In India, chromosomal disorders (e.g., trisomy 21, sex chromosome anomalies, structural rearrangements) contribute significantly to intellectual disability, congenital malformations, infertility, and recurrent pregnancy loss (prevalence ~1 in 160 births for major aneuploidies, higher in advanced maternal age). Karyotyping visualizes all 46 chromosomes to identify numerical and large structural changes. High morbidity from underdiagnosis in rural/low-SES families, limited cytogenetics labs outside metros, delayed diagnosis leading to missed early interventions, recurrence risk, or unnecessary suffering. Per cytogenetics practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs standard G-banding karyotyping over 1-2 days with high accuracy for gross abnormalities, valuable for postnatal evaluation in developmental delay, dysmorphism, or infertility. This diagnostic falls under genetic screening and targets children/adults with suspected chromosomal conditions, addressing accurate detection to guide management, therapy, and family counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating reproductive decisions, and reducing genetic disease burden. Its whole blood-based approach ensures reliable performance in India's expanding genetic diagnostic network.**Other Names**: Karyotype Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics, compliant with 2025 standards.**Historical Milestone**: G-banding karyotyping standard since 1970s; in India, essential in genetic clinics for decades.**Purpose**: The test performs 3 parameters including karyotype analysis to guide detection of chromosomal abnormalities, identify numerical/structural changes, inform genetic counseling report.**Test Parameters**: 1. Karyotype Analysis, 2. Chromosomal Abnormalities, 3. Genetic Counseling Report.**Pretest Condition**: No fasting required; patients should report developmental delay, dysmorphism, infertility, or recurrent pregnancy loss.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for karyotyping).**Medical History**: Patients should provide details on developmental milestones, dysmorphic features, infertility history, family genetic disorders.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed chromosomal abnormalities including recurrence or disability, benefits of detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using karyotyping (G-banding) by trained personnel to ensure sterile technique, culture cells, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or poor cell growth can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal karyotype indicates chromosomal disorder, necessitating specialist input and counseling. Normal may require follow-up if symptoms suggestive.**Specialist Consultation**: Geneticists or pediatricians should be consulted for interpretation and counseling.**Additional Supporting Tests**: Chromosomal microarray or FISH for confirmation of subtle changes.**Test Limitations**: Detects only gross abnormalities (≥5-10 Mb); misses microdeletions; comprehensive approach required.**References**: Indian Journal of Medical Genetics 2024, Cytogenetics Studies India 2023. |
